Literature DB >> 32950572

Metabolic mechanism and anti-inflammation effects of sinomenine and its major metabolites N-demethylsinomenine and sinomenine-N-oxide.

Qiang Li1, Wenbin Zhou2, Yuyan Wang1, Fang Kou1, Chunming Lyu3, Hai Wei4.   

Abstract

AIMS: Sinomenine (SIN) is clinically used as an anti-rheumatic drug. However, the metabolic and pharmacological mechanisms of SIN combined with its metabolites are unclear. This study aims to explore the cyclic metabolic mechanism of SIN, the anti-inflammation effects of SIN and its major metabolites (N-demethylsinomenine (DS) and sinomenine-N-oxide (SNO)), and the oxidation property of SNO.
MATERIALS AND METHODS: SIN was administrated to rats via gavage. Qishe pills (a SIN-containing drug) were orally administrated to humans. The bio-samples were collected to identify SIN's metabolites. Enzymatic and non-enzymatic incubations were used to reveal SIN's metabolic mechanism. Impacts of SIN, SNO and DS on the inflammation-related cytokine's levels and nuclear translocation of NF-κB were evaluated in LPS-induced Raw264.7 cells. ROS induced by SNO (10 μM) was also assessed. KEY
FINDINGS: CYP3A4 and ROS predominantly mediated the formation of SNO, and CYP3A4 and CYP2C19 primarily mediated the formation of DS. Noteworthily, SNO underwent N-oxide reduction both enzymatically, by xanthine oxidase (XOD), and non-enzymatically, by ferrous ion and heme moiety. The levels of IL-6 and TNF-α and nuclear translocation of NF-κB were ameliorated after pretreatment of SIN in LPS-induced Raw264.7 cells, while limited attenuations were observed after pretreatment of DS (SNO) even at 200 μM. In contrast, SNO induced ROS production. SIGNIFICANCE: This study elucidated that SIN underwent both enzymatic and non-enzymatic cyclic metabolism and worked as the predominant anti-inflammation compound, while SNO induced ROS production, suggesting more studies of SIN combined with SNO and DS are necessary in case of DDI and potential toxicities.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-inflammation effects; CYP450s; Dexamethasone; Heme moiety; Lipopolysaccharide; N-demethylsinomenine; ROS (reactive oxygen species); Sinomenine; Sinomenine-N-oxide

Mesh:

Substances:

Year:  2020        PMID: 32950572     DOI: 10.1016/j.lfs.2020.118433

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Sex-related differences in safety profiles, pharmacokinetics and tissue distribution of sinomenine hydrochloride in rats.

Authors:  Hong Huang; Er-Bing Zhang; Ou-Yang Yi; Han Wu; Guiming Deng; Yu-Ming Huang; Wen-Liang Liu; Jian-Ye Yan; Xiong Cai
Journal:  Arch Toxicol       Date:  2022-08-30       Impact factor: 6.168

2.  Zhengqing fengtongning sustained-release tablets prevents gout flares in the process of ULT: A randomized, positive control, double-blind, double-simulation, multicenter trial.

Authors:  Ertao Jia; Shasha Hu; Hongling Geng; Haiqiong Zhu; Jingjing Xie; Yuya Xiao; Yubao Jiang; Min Xiao; Jianyong Zhang
Journal:  Medicine (Baltimore)       Date:  2022-05-06       Impact factor: 1.817

3.  N-Demethylsinomenine, an active metabolite of sinomenine, attenuates chronic neuropathic and inflammatory pain in mice.

Authors:  Zhiyong Zhou; Nanqing Qiu; Yuntao Ou; Qianqian Wei; Wenting Tang; Mingcong Zheng; Yaluan Xing; Jie-Jia Li; Yong Ling; Junxu Li; Qing Zhu
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.